Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

BACKGROUND: This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), who had progressed after irinotecan-based chemotherapy. METHODS: In Phase I, in a 3+3 dose...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Samalin, E, Bouché, O, Thézenas, S, Francois, E, Adenis, A, Bennouna, J, Taieb, J, Desseigne, F, Seitz, J F, Conroy, T, Galais, M P, Assenat, E, Crapez, E, Poujol, S, Bibeau, F, Boissière, F, Laurent-Puig, P, Ychou, M, Mazard, T
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2014
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950852/
https://ncbi.nlm.nih.gov/pubmed/24407191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.813
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki